Treatment options in recurrent cervical cancer

Oncology Letters

Volumn 1, Issue 1, 2010, Pages 3-11

  Gadducci, Angiolo ^a   Tana, Roberta ^a   Cosio, Stefania ^a   Cionini, Luca ^a  

^a UNIVERSITY OF PISA   (Italy)

Author keywords

Chemo radiation; Cisplatin; Combination chemotherapy; Molecularly targeted therapy; Pelvic exenteration; Radiotherapy; Recurrence; Surgery

Indexed keywords

BEVACIZUMAB; BLEOMYCIN; CARBOPLATIN; CETUXIMAB; CISPLATIN; DOCETAXEL; FLUOROURACIL; GEMCITABINE; IFOSFAMIDE; IRINOTECAN; NAVELBINE; PACLITAXEL; PEMETREXED; TOPOTECAN; VINDESINE;

CANCER COMBINATION CHEMOTHERAPY; CANCER MORTALITY; CANCER RADIOTHERAPY; CANCER RELAPSE; CANCER SURGERY; CLINICAL TRIAL; COLORECTAL ANASTOMOSIS; CONTROLLED STUDY; DISEASE FREE INTERVAL; DRUG EFFICACY; DRUG RESPONSE; FISTULA; HUMAN; INTENSITY MODULATED RADIATION THERAPY; LUNG METASTASIS; MYOCUTANEOUS FLAP; OVERALL SURVIVAL; PARAAORTIC LYMPH NODE; PELVIS EXENTERATION; PROGNOSIS; QUALITY OF LIFE; RADIATION DOSE; RADICAL HYSTERECTOMY; RECOMMENDED DRUG DOSE; RECURRENT CANCER; REVIEW; SINGLE DRUG DOSE; SURGICAL MORTALITY; TREATMENT RESPONSE; TUMOR VOLUME; URINARY TRACT INJURY; UTERINE CERVIX CANCER; VAGINA RECONSTRUCTION;

EID: 77955747607     PISSN: 17921074     EISSN: 17921082     Source Type: Journal    
DOI: 10.3892/ol_00000001     Document Type: Review

References (140)

1. Parkin DM, Bray F, Ferlay J and Pisani P: Global cancer statistics, 2002. CA Cancer J Clin 55: 74-108, 2005.
2. Bellone S, Pecorelli S, Cannon MJ and Santin AD: Advances in dendritic-cell-based therapeutic vaccines for cervical cancer. Expert Rev Anticancer Ther 7: 1473-1486, 2007.
3. Leitao MM and Chi DS: Recurrent cervical cancer. Curr Treat Options Oncol 3: 105-111, 2002.
4. Friedlander M: Guidelines for the treatment of recurrent and metastatic cervical cancer. Oncologist 7: 342-347, 2002.
5. Quinn MA, Benedet JL, Odicino F, Maisonneuve P, Beller U, Creasman WT, Heintz APM, Ngan HYS and Pecorelli S: Carcinoma of the cervix uteri. Int J Gynecol Obstet 95 (Suppl 1): 43-103, 2006.
6. Dornhöfer N and Höckel M: New developments in the surgical therapy of cervical carcinoma. Ann NY Acad Sci 1138: 233-252, 2008.
7. Höckel M: Pelvic recurrences of cervical cancer. Relapse pattern, prognostic factors and the role of extended radical treatment. J Pelv Surg 5: 255-266, 1999.
8. Zatoński W and Tyczyński J: Cancer in Poland in 1993. Zakład Epidemiologii i Prewencji Nowotworów. Krajowy Rejestr Nowotworów, Warszawa, pp22-41, 1996.
9. Panek G, Gawrychowski K, Sobiczewski P, Derlatka P, Danska-Bidzinska A, Gmyrek L and Bidzinski M: Results of chemotherapy for pulmonary metastases of carcinoma of the cervix in patients after primary surgical and radiotherapeutic management. Int J Gynecol Cancer 17: 1056-1061, 2007.
10. Zola P, Fuso L, Mazzola S, Piovano E, Perotto S, Gadducci A, Galletto L, Landoni F, Maggino T, Raspagliesi F, Sartori E and Scambia G: Could follow-up different modalities play a role in asymptomatic cervical cancer relapses diagnosis? An Italian multicenter retrospective analysis. Gynecol Oncol 107 (Suppl 1): 150-154, 2007.
11. Potter ME, Alvarez RD, Gay FL, Shingleton HM, Soong SJ and Hatch KD: Optimal therapy for pelvic recurrence after radical hysterectomy for early-stage cervical cancer. Gynecol Oncol 37: 74-77, 1990.
12. Malfetano J, Keys H, Kredentser D, Cunningham M, Kotlove D and Weiss L: Weekly cisplatin and radical radiation therapy for advanced, recurrent and poor prognosis cervical carcinoma. Cancer 71: 3703-3706, 1993.
13. Ijaz T, Eifel PJ, Burke T and Oswald MJ: Radiation therapy of pelvic recurrence after radical hysterectomy for cervical carcinoma. Gynecol Oncol 70: 241-246, 1998.
14. Smaniotto D, D'Agostino G, Luzi S, Valentini V, Macchia G G, Mantini G, Margariti PA, Ferrandina G and Scambia G: Concurrent 5-fluorouracil, mitomycin C and radiation with or without brachytherapy in recurrent cervical cancer: a scoring system to predict clinical response and outcome. Tumori 91: 295-301, 2005.
15. Windschall A, Ott OJ, Sauer R and Strnad V: Radiation therapy and simultaneous chemotherapy for recurrent cervical carcinoma. Strahlenther Onkol 181: 545-550, 2005.
16. Miglietta L, Franzone P, Centurioni MG, Boni L, Tacchini L, Cosso M, Boccardo F, Ferrarini M and Bruzzone M: A phase II trial with cisplatin-paclitaxel cytotoxic treatment and concurrent external and endocavitary radiation therapy in locally advanced or recurrent cervical cancer. Oncology 70: 19-24, 2006.
17. Jain P, Hunter RD, Livsey JE, Coyle C, Swindell R and Davidson SE SE: Salvaging locoregional recurrence with radiotherapy after surgery in early cervical cancer. Clin Oncol (R Coll Radiol) 19: 763-768, 2007.
18. Piura B, Rabinovich A and Friger M: Recurrent cervical carcinoma after radical hysterectomy and pelvic lymph node dissection: a study of 32 cases. Eur J Gynaecol Oncol 29: 31-36, 2008.
19. Barter JF, Soong SJ, Shingleton HM, Hatch KD and Orr JW Jr: Complications of combined radical hysterectomy-postoperative radiation therapy in women with early stage cervical cancer. Gynecol Oncol 32: 292-296, 1989.
20. Magrina JF: Complications of irradiation and radical surgery for gynecologic malignancies. Obstet Gynecol Surv 48: 571-575, 1993.
21. Mundt AJ, Roeske JC, Lujan AE, Yamada SD, Waggoner SE, Fleming G and Rotmensch J: Initial clinical experience with intensity-modulated whole-pelvis radiation therapy in women with gynecologic malignancies. Gynecol Oncol 82: 456-463, 2003.
22. Friedell GH, Cesare F and Parson L: Surgical treatment of cancer of the cervix recurring after primary irradiation therapy. N Engl J Med 264: 781-784, 1961.
23. Rubin SC, Hoskins WJ and Lewis JL: Radical hysterectomy for recurrent cervical cancer following radiation therapy. Gynecol Oncol 27: 316-324, 1987.
24. Terada K and Morley GW: Radical hysterectomy as surgical salvage therapy for gynecologic malignancy. Obstet Gynecol 70: 913-915, 1987.
25. Rutledge S, Carey MS, Prichard H, Allen HH, Kocha W and Kirk ME: Conservative surgery for recurrent or persistent carcinoma of the cervix following irradiation: is exenteration always necessary? Gynecol Oncol 52: 353-359, 1994.
26. Coleman RL, Keeney ED, Freedman RS, Burke TW, Eifel PJ and Rutledge FN: Radical hysterectomy for recurrent carcinoma of the uterine cervix after radiotherapy. Gynecol Oncol 55: 29-35, 1994.
27. Maneo A, Landoni F, Cormio G, Colombo A and Mangioni C: Radical hysterectomy for recurrent or persistent cervical cancer following radiation therapy. Int J Gynecol Cancer 9: 295-301, 1999.
28. Magrina JF: Types of pelvic exenterations: a reappraisal. Gynecol Oncol 37: 363-366, 1990.
29. Magrina JF, Stanhope CR and Weaver AL: Pelvic exenterations: supralevator, infralevator, and with vulvectomy. Gynecol Oncol 64: 130-135, 1997.
30. Chiva LM, Lapuente F, González-Cortijo L, González-Martín A, Rojo A, García JF and Carballo N: Surgical treatment of recurrent cervical cancer: state of the art and new achievements. Gynecol Oncol 110 (Suppl 2): 60-66, 2008.
31. Brunschwig A and Barber HR: Extended pelvic exenteration for advanced cancer of the cervix. Long survivals following added resection of involved small bowel. Cancer 17: 1267-1270, 1964.
32. Kiselow M, Butcher HR Jr and Bricker EM: Results of the radical surgical treatment of advanced pelvic cancer: a fifteen-year study. Ann Surg 166: 428-436, 1967.
33. Creasman WT and Rutledge F: Is positive pelvic lymphadenopathy a contraindication to radical surgery in recurrent cervical carcinoma? Gynecol Oncol 2: 482-485, 1974.
34. Rutledge FN, Smith JP, Wharton JT and O'Quinn AG: Pelvic exenteration: analysis of 296 patients. Am J Obstet Gynecol 129: 881-892, 1977.
35. Symmonds RE, Pratt JH and Webb MJ: Exenterative operations: experience with 198 patients. Am J Obstet Gynecol 121: 907-918, 1975.
36. Karlen JR and Piver MS: Reduction of mortality and morbidity associated with pelvic exenteration. Gynecol Oncol 3: 164-167, 1975.
37. Morley GW, Hopkins MP, Lindenauer SM and Roberts JA: Pelvic exenteration, University of Michigan: 100 patients at 5 years. Obstet Gynecol 74: 934-943, 1989.
38. Shingleton HM, Soong SJ, Gelder MS, Hatch KD, Baker VV and Austin JM Jr: Clinical and histopathologic factors predicting recurrence and survival after pelvic exenteration for cancer of the cervix. Obstet Gynecol 73: 1027-1034, 1989.
39. Marnitz S, Köhler C, Müller M, Behrens K, Hasenbein K and Schneider A: Indications for primary and secondary exenterations in patients with cervical cancer. Gynecol Oncol 103: 1023-1030, 2006.
40. Goldberg GLGL, Sukumvanich P, Einstein MH, Smith HO, Anderson PS and Fields AL: Total pelvic exenteration: the Albert Einstein College of Medicine/Montefiore Medical Center Experience (1987 to 2003). Gynecol Oncol 101: 261-268, 2006.
41. Berek JS, Howe C, Lagasse LD and Hacker NF: Pelvic exenteration for recurrent gynecologic malignancy: survival and morbidity analysis of the 45-year experience at UCLA. Gynecol Oncol 99: 153-159, 2005.
42. Crozier M, Morris M, Levenback C, Lucas KR, Atkinson EN and Wharton JT: Pelvic exenteration for adenocarcinoma of the uterine cervix. Gynecol Oncol 58: 74-78, 1995.
43. Fleisch MC, Pantke P, Beckmann MW, Schnuerch HG, Ackermann R, Grimm MO, Bender HG and Dall P: Predictors for long-term survival after interdisciplinary salvage surgery for advanced or recurrent gynecologic cancers. J Surg Oncol 95: 476-484, 2007.
44. Kinkel K, Ariche M, Tardivon AA, Spatz A, Castaigne D, Lhomme C and Vanel D: Differentiation between recurrent tumor and benign conditions after treatment of gynecologic pelvic carcinoma: value of dynamic contrast-enhanced subtraction MR imaging. Radiology 204: 55-63, 1997.
45. Popovich MJ, Hricak H, Sugimura K and Stern JL: The role of MR imaging in determining surgical eligibility for pelvic exenteration. AJR Am J Roentgenol 160: 525-531, 1993.
46. Jeong YY, Kang HK, Chung TW, Seo JJ and Park JG: Uterine cervical carcinoma after therapy: CT and MR imaging findings. Radiographics 23: 969-981, 2003.
47. Elst P, Ahankour F and Tjalma W: Management of recurrent cervical cancer. Review of the literature and case report. Eur J Gynaecol Oncol 28: 435-441, 2007.
48. Husain A, Akhurst T, Larson S, Alektiar K, Barakat RR and Chi DS: A prospective study of the accuracy of 18fluorodeoxyglucose positron emission tomography (18FDG PET) in identifying sites of metastasis prior to pelvic exenteration. Gynecol Oncol 106: 177-180, 2007.
49. Babar S, Rockall A, Goode A, Shepherd J and Reznek R: Magnetic resonance imaging appearances of recurrent cervical carcinoma. Int J Gynecol Cancer 17: 637-645, 2007.
50. Jover R, Lourido D, Gonzalez C, Rojo A, Gorospe L and Alfonso JM: Role of PET /CT in the evaluation of cervical cancer. Gynecol Oncol 110 (Suppl 2): 55-59, 2008.
51. Höckel M and Dornhöfer N: Pelvic exenteration for gynaecologic tumours: achievements and unanswered questions. Lancet Oncol 7: 837-847, 2006.
52. Plante M and Roy M: Operative laparoscopy prior to a pelvic exenteration in patients with recurrent cervical cancer. Gynecol Oncol 69: 94-99, 1998.
53. Kohler C, Tozzi R, Possover M and Schneider A: Explorative laparoscopy prior to exenterative surgery. Gynecol Oncol 86: 311-315, 2002.
54. Stein P, Daneshmand S, Dunn M, Garcia M, Lieskovsky G and Skinner DG: Continent right colon reservoir using a cutaneous appendicostomy. Urology 63: 577-580, 2004.
55. Rowland RG and Kropp BP: Evolution of the Indiana continent urinary reservoir. J Urol 152: 2247-2251, 1994.
56. Bihrle R: The Indiana pouch continent urinary reservoir. Urol Clin North Am 24: 773-779, 1997.
57. Salom EM, Mendez LE, Schey D, Lambrou N, Kassira N, Gómez-Marn O, Averette H and Peñalver M: Continent ileocolonic urinary reservoir (Miami pouch): the University of Miami experience over 15 years. Am J Obstet Gynecol 190: 994-1003, 2004.
58. Angioli R, Benedetti Panici P, Mirhashemi R, Mendez L, Cantuaria G, Basile S and Penalver M: Continent urinary diversion and low colorectal anastomosis after pelvic exenteration. Quality of life and complication risk. Crit Rev Oncol Hematol 48: 281-285, 2003.
59. Benedetti Panici P, Angioli R, Plotti F, Muzii L, Zullo MA, Manci N, Palaia I and Galluci M: Continent ileocolonic urinary diversion (Rome pouch) for gynecologic malignancies: technique and feasibility. Gynecol Oncol 107: 194-199, 2007.
60. Hatch KD, Gelder MS, Soong SJ, Baker VV and Shingleton HM: Pelvic exenteration with low rectal anastomosis: survival, complications, and prognostic factors. Gynecol Oncol 38: 462-467, 1990.
61. Rietjens M, Maggioni A, Bocciolone L, Sideri M, Youssef O and Petit JY: Vaginal reconstruction after extended radical pelvic surgery for cancer: comparison of two techniques. Plast Reconstr Surg 109: 1592-1599, 2002.
62. Green AE, Escobar PF, Neubaurer N, Michener CM and Vongruenigen VE: The Martius flap neovagina revisited. Int J Gynecol Cancer 15: 964-966, 2005.
63. O'Connell C, Mirhashemi R, Kassira N, Lambrou N and McDonald WS: Formation of functional neovagina with vertical rectus abdominis musculocutaneous (VRAM) flap after total pelvic exenteration. Ann Plast Surg 55: 470-473, 2005.
64. Del Carmen MG, McIntyre JF and Goodman A: The role of intraoperative radiation therapy (IORT) in the treatment of locally advanced gynecologic malignancies. Oncologist 5: 18-25, 2000.
65. Gemignani ML, Alektiar KM, Leitao M, Mychalczak B, Chi D, Venkatraman E, Barakat RR and Curtin JP: Radical surgical resection and high-dose intraoperative radiation therapy (HDR-IORT) in patients with recurrent gynecologic cancers. Int J Radiat Oncol Biol Phys 50: 687-694, 2001.
66. Hicks ML, Piver MS, Mas E, Hempling RE, Mcauley M and Walsh DL: Intraoperative orthovoltage radiation therapy in the treatment of recurrent gynecologic malignancies. Am J Clin Oncol 16: 497-500, 1993.
67. Höckel M: Laterally extended endopelvic resection: novel surgical treatment of locally recurrent cervical carcinoma involving the pelvic side wall. Gynecol Oncol 91: 369-377, 2003.
68. Höckel M: Laterally extended endopelvic resection (LEE R) - principles and practice. Gynecol Oncol 111: S13-S17, 2008.
69. Lopez-Graniel C, Dolores R, Cetina L, Gonzalez A, Cantu D, Chanona J, Uribe J, Candelaria M, Brom R, de la Garza J and Duenas-Gonzalez A: Pre-exenterative chemotherapy, a novel therapeutic approach for patients with persistent or recurrent cervical cancer. BMC Cancer 5: 118, 2005.
70. Hogg R and Friedlander M: Role of systemic chemotherapy in metastatic cervical cancer. Expert Rev Anticancer Ther 3: 234-240, 2003.
71. Tambaro R, Scambia G, di Maio M, Pisano C, Barletta E, Iaffaioli VR and Pignata S: The role of chemotherapy in locally advanced, metastatic and recurrent cervical cancer. Crit Rev Oncol Hematol 52: 33-44, 2004.
72. Pectasides D, Kamposioras K, Papaxoinis G and Pectasides E: Chemotherapy for recurrent cervical cancer. Cancer Treat Rev 34: 603-613, 2008.
73. Carl UM, Bahnsen J and Rapp W: Radiation therapy of para-aortic lymph nodes in gynaecologic cancers: techniques, results and complications. Strahlenther Onkol 168: 383-389, 1992.
74. Grigsby PW, Vest ML and Perez CA: Recurrent carcinoma of the cervix exclusively in the paraaortic nodes following radiation therapy. Int J Radiat Oncol Biol Phys 28: 451-455, 1994.
75. Chou HH, Wang CC, Lai CH, Hong JH, Ng KK, Chang TC, Tseng CJ, Tsai CS and Chang JT: Isolated paraaortic lymph node recurrence after definitive irradiation for cervical carcinoma. Int J Radiat Oncol Biol Phys 51: 442-448, 2001.
76. Singh AK, Grigsby PW, Rader JS, Mutch DG and Powell MA: Cervix carcinoma, concurrent chemoradiotherapy and salvage of isolated paraaortic lymph node recurrence. Int J Radiat Oncol Biol Phys 61: 450-455, 2005.
77. Kim JS, Kim JS, Kim SY, Kim KH and Cho MJ: Hyperfractionated radiotherapy with concurrent chemotherapy for para-aortic lymph node recurrence in carcinoma of the cervix. Int J Radiat Oncol Biol Phys 55: 1247-1253, 2003.
78. DuPont NC and Monk BJ: Chemotherapy in the management of cervical carcinoma. Clin Adv Hematol Oncol 4: 279-286, 2006.
79. Thigpen T, Shingleton H, Homesley H, Lagasse L and Blessing J: Cis-platin in treatment of advanced or recurrent squamous cell carcinoma of the cervix: a phase II study of the Gynecologic Oncology Group Cancer 48: 899-903, 1981.
80. Bonomi P, Blessing JA, Stehman FB, DiSaia PJ, Walton L and Major FJ: Randomized trial of three cisplatin dose schedules in squamous-cell carcinoma of the cervix: a Gynecologic Oncology Group study. J Clin Oncol 3: 1079-1085, 1985.
81. Thigpen JT, Blessing JA, Fowler WC Jr and Hatch K: Phase II trials of cisplatin and piperazinedione as single agents in the treatment of advanced or recurrent non-squamous cell carcinoma of the cervix: a Gynecologic Oncology Group Study. Cancer Treat Rep 70: 1097-1100, 1986.
82. Thigpen JT, Blessing JA, DiSaia PJ, Fowler WC Jr and Hatch KD: A randomized comparison of a rapid versus prolonged (24 h) infusion of cisplatin in therapy of squamous cell carcinoma of the uterine cervix: a Gynecologic Oncology Group study. Gynecol Oncol 32: 198-202, 1989.
83. Lele SB and Piver MS: Weekly cisplatin induction chemotherapy in the treatment of recurrent cervical carcinoma. Gynecol Oncol 33: 6-8, 1989.
84. Potter ME, Hatch KD, Potter MY, Shingleton HM and Baker VV: Factors affecting the response of recurrent squamous cell carcinoma of the cervix to cisplatin. Cancer 63: 1283-1286, 1989.
85. Arseneau J, Blessing JA, Stehman FB and McGehee R: A phase II study of carboplatin in advanced squamous cell carcinoma of the cervix (a Gynecologic Oncology Group Study). Invest New Drugs 4: 187-191, 1986.
86. McGuire WP III, Arseneau J, Blessing JA, DiSaia PJ, Hatch KD, Given FT Jr, Teng NN and Creasman WT: A randomized comparative trial of carboplatin and iproplatin in advanced squamous carcinoma of the uterine cervix: a Gynecologic Oncology Group study. J Clin Oncol 7: 1462-1468, 1989.
87. Weiss GR, Green S, Hannigan EV, Boutselis JG, Surwit EA, Wallace DL and Alberts DS: A phase II trial of carboplatin for recurrent or metastatic squamous carcinoma of the uterine cervix: a Southwest Oncology Group study. Gynecol Oncol 39: 332-336, 1990.
88. Meanwell CA, Mould JJ, Blackledge G, Lawton FG, Stuart NS, Kavanagh J, Latief TN, Spooner D and Chetiyawardana AD: Phase II study of ifosfamide in cervical cancer. Cancer Treat Rep 70: 727-730, 1986.
89. Sutton GP, Blessing JA, Adcock L, Webster KD and DeEulis T: Phase II study of ifosfamide and mesna in patients with previously-treated carcinoma of the cervix: a Gynecologic Oncology Group study. Invest New Drugs 7: 341-343, 1989.
90. Sutton GP, Blessing JA, DiSaia PJ and McGuire WP: Phase II study of ifosfamide and mesna in nonsquamous carcinoma of the cervix: a Gynecologic Oncology Group study. Gynecol Oncol 49: 48-50, 1993.
91. Rhomberg WU: Vindesine for recurrent and metastatic cancer of the uterine cervix: a phase II study. Cancer Treat Rep 70: 1455-1457, 1986.
92. Morris M, Brader KR, Levenback C, Burke TW, Atkinson EN, Scott WR and Gershenson DM: Phase II study of vinorelbine in advanced and recurrent squamous cell carcinoma of the cervix. J Clin Oncol 16: 1094-1098, 1998.
93. Lhommé C, Vermorken JB, Mickiewicz E, Chevalier B, Alvarez A, Mendiola C, Pawinski A, Lentz MA and Pecorelli S S: Phase II trial of vinorelbine in patients with advanced and/or recurrent cervical carcinoma: an EORTC EORTC Gynaecological Cancer Cooperative Group study. Eur J Cancer 36: 194-199, 2000.
94. Muggia FM, Blessing JA, Waggoner S, Berek JS, Monk B BJ, Sorosky J and Pearl ML: Evaluation of vinorelbine in persistent or recurrent nonsquamous carcinoma of the cervix: a Gynecologic Oncology Group Study. Gynecol Oncol 96: 108-111, 2005.
95. Schilder RJ, Blessing JA, Morgan M, Mangan CE and Rader JS: Evaluation of gemcitabine in patients with squamous cell carcinoma of the cervix: a phase II study of the gynecologic oncology group. Gynecol Oncol 76: 204-207, 2000.
96. Schilder RJ, Blessing J and Cohn DE: Evaluation of gemcitabine in previously treated patients with non-squamous cell carcinoma of the cervix: a phase II study of the Gynecologic Oncology Group. Gynecol Oncol 96: 103-107, 2005.
97. McGuire WP, Blessing JA, Moore D, Lentz SS and Photopulos G G: Paclitaxel has moderate activity in squamous cervix cancer: a Gynecologic Oncology Group study. J Clin Oncol 14: 792-795, 1996.
98. Kudelka AP, Winn R, Edwards CL, Downey G, Greenberg H, Dakhil SR, Freedman RS, Loyer E, Rusinkiewicz J, Gacrama P, Fueger R and Kavanagh JJ: Activity of paclitaxel in advanced or recurrent squamous cell cancer of the cervix. Clin Cancer Res 2: 1285-1288, 1996.
99. Kudelka AP, Winn R, Edwards CL, Downey G, Greenberg H, Dakhil SR, Freedman RS, LoCoco S, Umbreit J, Delmore JE, Arbuck S, Loyer E, Gacrama P, Fueger R and Kavanagh JJ: An update of a phase II study of paclitaxel in advanced or recurrent squamous cell cancer of the cervix. Anticancer Drugs 8: 657-661, 1997.
100. Curtin JP, Blessing JA, Webster KD, Rose PG, Mayer AR, Fowler WC Jr, Malfetano JH and Alvarez RD: Paclitaxel, an active agent in nonsquamous carcinomas of the uterine cervix: a Gynecologic Oncology Group Study. J Clin Oncol 19: 1275-1278, 2001.
101. Garcia AA, Blessing JA, Vaccarello L and Roman LD: Gynecologic Oncology Group Study: phase II clinical trial of docetaxel in refractory squamous cell carcinoma of the cervix: a Gynecologic Oncology Group Study. Am J Clin Oncol 30: 428-431, 2007.
102. Bookman MA, Blessing JA, Hanjani P, Herzog TJ and Andersen WA: Topotecan in squamous cell carcinoma of the cervix: a phase II study of the Gynecologic Oncology Group. Gynecol Oncol 77: 446-449, 2000.
103. Muderspach LI, Blessing JA, Levenback C and Moore JL Jr: A Phase II study of topotecan in patients with squamous cell carcinoma of the cervix: a Gynecologic Oncology Group study, Gynecol Oncol 81: 213-215, 2001.
104. Verschraegen CF, Levy T, Kudelka AP, Llerena E, Ende K, Freedman RS, Edwards CL, Hord M, Steger M, Kaplan AL, Kieback D, Fishman A and Kavanagh JJ: Phase II study of irinotecan in prior chemotherapy-treated squamous cell carcinoma of the cervix. J Clin Oncol 15: 625-631, 1997.
105. Lhommé C, Fumoleau P, Fargeot P, Krakowski Y, Dieras V, Chauvergne J, Vennin P, Rebattu P, Roche H, Misset JL, Lentz MA, van Glabbeke M, Matthieu-Boué A, Mignard D and Chevallier B: Results of a European Organization for Research and Treatment of Cancer/Early Clinical Studies Group phase II trial of first-line irinotecan in patients with advanced or recurrent squamous cell carcinoma of the cervix. J Clin Oncol 17: 3136-3142, 1999.
106. Goedhals L, van Wiyk AL, Smith BL and Fourie SJ: Pemetrexed (Alimta, LY231514) demonstrates clinical activity in chemonaive patients with cervical cancer in a phase II single-agent trial. Int J Gynecol Cancer 16: 1172-1178, 2006.
107. Miller DS, Blessing JA, Bodurka DC, Bonebrake AJ and Schorge JO: Gynecologic Oncology Group: evaluation of pemetrexed (Alimta, LY231514) as second line chemotherapy in persistent or recurrent carcinoma of the cervix: a phase II study of the Gynecologic Oncology Group. Gynecol Oncol 110: 65-70, 2008.
108. Ferrandina G, Lorusso D, Ludovisi M, Pignata S, Sorio R, Mangili G, Breda E, Legge F, Pisconti S and Scambia G: Phase II study on pemetrexed in advanced/or recurrent cervical cancer patients: a MITO study. J Oncol 26 (Suppl 296): abs. 5515, 2008.
109. Bonomi P, Blessing J, Ball H, Hanjani P and DiSaia PJ: A phase II evaluation of cisplatin and 5-fluorouracil in patients with advanced squamous cell carcinoma of the cervix: a Gynecologic Oncology Group study. Gynecol Oncol 34: 357-359, 1989.
110. Kaern J, Tropé C, Sundfoer K and Kristensen GB: Cisplatin/5-fluorouracil treatment of recurrent cervical carcinoma: a phase II study with long-term follow-up. Gynecol Oncol 60: 387-392, 1996.
111. Kaern J, Tropé C, Abeler V, Iversen T and Kjørstad K: A phase II study of 5-fluorouracil/cisplatinum in recurrent cervical cancer. Acta Oncol 29: 25-28, 1990.
112. Benjapibal M, Thirapakawong C, Leelaphatanadit C, Therasakvichya S and Inthasorn P: A pilot phase II study of capecitabine plus cisplatin in the treatment of recurrent carcinoma of the uterine cervix. Oncology 72: 33-38, 2007.
113. Daghestani N, Hakes TB, Lynch G and Lewis JL Jr: Cervix carcinoma: treatment with combination cisplatin and bleomycin. Gynecol Oncol 16: 334-339, 1983.
114. Coleman RE, Clarke JM, Slevin ML, Sweetenham J, Williams C CJ, Blake P, Calman F, Wiltshaw E and Harper PG: A phase II study of ifosfamide and cisplatin chemotherapy for metastatic or relapsed carcinoma of the cervix. Cancer Chemother Pharmacol 27: 52-54, 1990.
115. Cervellino JC, Araujo CE, Sánchez O, Miles H and Nishihama A: Cisplatin and ifosfamide in patients with advanced squamous cell carcinoma of the uterine cervix. A phase II trial. Acta Oncol 34: 257-259, 1995.
116. Burnett AF, Roman LD, Garcia AA, Muderspach LI, Brader KR and Morrow CP: A phase II study of gemcitabine and cisplatin in patients with advanced, persistent, or recurrent squamous cell carcinoma of the cervix. Gynecol Oncol 76: 63-66, 2000.
117. Sugiyama T, Nishida T, Kumagai S, Nishio S, Fujiyoshi K, Okura N, Yakushiji M, Hiura M and Umesaki N: Combination therapy with irinotecan and cisplatin as neoadjuvant chemotherapy in locally advanced cervical cancer. Br J Cancer 81: 95-98, 1999.
118. Sugiyama T, Yakushiji M, Noda K, Ikeda M, Kudoh R, Yajima A, Tomoda Y, Terashima Y, Takeuchi S, Hiura M, Saji F, Takahashi T, Umesaki N, Sato S, Hatae M and Ohashi Y: Phase II study of irinotecan and cisplatin as first-line chemotherapy in advanced or recurrent cervical cancer. Oncology 58: 31-37, 2000.
119. Rose PG, Blessing JA, Gershenson DM and McGehee R: Paclitaxel and cisplatin as first-line therapy in recurrent or advanced squamous cell carcinoma of the cervix: a Gynecologic Oncology Group study. J Clin Oncol 17: 2676-2680, 1999.
120. Papadimitriou CA, Sarris K, Moulopoulos LA, Fountzilas G, Anagnostopoulos A, Voulgaris Z, Gika D, Giannakoulis N, Diakomanolis E and Dimopoulos MA: Phase II trial of paclitaxel and cisplatin in metastatic and recurrent carcinoma of the uterine cervix. J Clin Oncol 17: 761-766, 1999.
121. Piver MS, Ghamande SA, Eltabbakh GH and O'Neill-Coppola C C: First-line chemotherapy with paclitaxel and platinum for advanced and recurrent cancer of the cervix - a phase II study. Gynecol Oncol 75: 334-337, 1999.
122. Long HJ III, Bundy BN, Grendys EC Jr, Benda JA, McMeekin DS, Sorosky J, Miller DS, Eaton LA and Fiorica JV: Randomized phase III trial of cisplatin with or without topotecan in carcinoma of the uterine cervix: a Gynecologic Oncology Group Study. J Clin Oncol 23: 4626-4633, 2005.
123. Monk BJ, Sill MW, McMeekin SD, Cohn DE, Ramondetta L LM, Boardman CH and Benda J: A randomized phase III trial of four cisplatin (CIS) containing doublet combinations in stage IVb, recurrent, or persistent cervical carcinoma: a Gynecologic Oncology Group (GOG) study. J Clin Oncol 26 (Suppl 294): abs. LB A 5504, 2008.
124. Wenzel LN, Huang H, Cella D, Monk BJ, Sill MW, McMeekin S SD, Cohn DE, Ramondetta LM, Boardman CH and Benda J: Quality-of-life results of a randomized phase III trial of four cisplatin (Cis) containing doublet combinations in stage Ivb cervical carcinoma: a Gynecologic Oncology Group (GOG) study. J Clin Oncol 26 (Suppl 300): abs. 5529, 2008.
125. Bloss JD, Blessing JA, Behrens BC, Mannel RS, Rader JS, Sood AK, Markman M and Benda J: Randomized trial of cisplatin and ifosfamide with or without bleomycin in squamous carcinoma of the cervix: a Gynecologic Oncology Group study. J Clin Oncol 20: 1832-1837, 2002.
126. Cadron I, Jakobsen A and Vergote I: Report of an early stopped randomized trial comparing cisplatin vs. cisplatin/ifosfamide/ 5-fluorouracil in recurrent cervical cancer. Gynecol Obstet Invest 59: 126-129, 2005.
127. Zanetta G, Fei F, Parma G, Balestrino M, Lissoni A, Gabriele A and Mangioni C: Paclitaxel, ifosfamide and cisplatin (TIP) chemotherapy for recurrent or persistent squamous-cell cervical cancer. Ann Oncol 10: 1171-1174, 1999.
128. Dimopoulos MA, Papadimitriou CA, Sarris K, Aravantinos G, Kalofonos C, Gika D, Gourgoulis GM, Efstathiou E, Skarlos D and Bafaloukos D: Combination of ifosfamide, paclitaxel, and cisplatin for the treatment of metastatic and recurrent carcinoma of the uterine cervix: a phase II study of the Hellenic Cooperative Oncology Group. Gynecol Oncol 85: 476-482, 2002.
129. Choi CH, Kim TJ, Lee SJ, Lee JW, Kim BG, Lee JH and Bae DS: Salvage chemotherapy with a combination of paclitaxel, ifosfa-mide, and cisplatin for the patients with recurrent carcinoma of the uterine cervix. Int J Gynecol Cancer 16: 1157-1164, 2006.
130. Van Luijk IF, Coens C, van der Burg ME, Kobierska A, Namer M, Lhomme C, Zola P, Zanetta G and Vermorken JB; Gynecological Cancer Group of the European Organization for Research and Treatment of Cancer: Phase II study of bleomycin, vindesine, mitomycin C and cisplatin (BEM P) in recurrent or disseminated squamous cell carcinoma of the uterine cervix. Ann Oncol 18: 275-281, 2007.
131. Buda A, Fossati R, Colombo N, Fei F, Floriani I, Gueli Alletti D, Katsaros D, Landoni F, Lissoni A, Malzoni C, Sartori E, Scollo P, Torri V, Zola P and Mangioni C: Randomized trial of neoadjuvant chemotherapy comparing paclitaxel, ifosfamide and cisplatin with ifosfamide and cisplatin followed by radical surgery in patients with locally advanced squamous cell cervical carcinoma: the SNAP01 (Studio Neo-Adjuvante Portio) Italian Collaborative Study. J Clin Oncol 23: 4137-4145, 2005.
132. Mourton SM, Sonoda Y, Abu-Rustum NR, Bochner BH, Barakat RR RR and Chi DS: Resection of recurrent cervical cancer after total pelvic exenteration. Int J Gynecol Cancer 17: 137-140, 2007.
133. Bodurka-Bevers D, Morris M, Eifel PJ, Levenback C, Bevers MW, Lucas KR and Wharton JT: Posttherapy surveillance of women with cervical cancer: an outcome analysis. Gynecol Oncol 78: 187-193, 2000.
134. Monk BJ, Sill MW, Burger RA, Gray HJ, Buekers TE and Roman LD: Phase II trial of bevacizumab in the treatment of persistent or recurrent squamous cell carcinoma of the cervix: a gynecologic oncology group study. J Clin Oncol 27: 1069-1074, 2009.
135. Coleman RL; Gynecologic Oncology Group's: The Gynecologic Oncology Group's role in the treatment of recurrent cervix cancer: current clinical trials. Gynecol Oncol 110 (Suppl 2): 77-80, 2008.
136. Bellone S, Frera G, Landolfi G, Romani C, Bandiera E, Tognon G, Roman JJ, Burnett AF, Pecorelli S and Santin AD: Overexpression of epidermal growth factor type-1 receptor (EGF-R1) in cervical cancer: implications for Cetuximab-mediated therapy in recurrent/metastatic disease. Gynecol Oncol 106: 513-520, 2007.
137. Goncalves A, Fabbro M, Lhommé C, Gladieff L, Extra JM, Floquet A, Chaigneau L, Carrasco AT and Viens P: A phase II trial to evaluate gefitinib as second- or third-line treatment in patients with recurring locoregionally advanced or metastatic cervical cancer. Gynecol Oncol 108: 42-46, 2008.
138. Del Campo JM, Prat A, Gil-Moreno A, Pérez J and Parera M: Update on novel therapeutic agents for cervical cancer. Gynecol Oncol 110 (Suppl 2): 72-76, 2008.
139. Hindenburg AA and Matthews L: Complete and sustained remission of refractory cervical cancer following a single cycle of capecitabine. A case report. Int J Gynecol Cancer 13: 898-900, 2003.
140. Khoury-Collado F, Bowes RJ, Jhamb N, Aghajanian C and Abu-Rustum NR: Unexpected long-term survival without evidence of disease after salvage chemotherapy for recurrent metastatic cervical cancer: a case series. Gynecol Oncol 105: 823-825, 2007.